12 years. 2+ billion doses and counting.
Our pipeline of medicines aims to overcome barriers that patients face with existing treatment options and provide new paradigms for treating critical and complex conditions.1
2B+ doses consumed. 200+ patents provide strong intellectual property.
Aquestive is the worldwide leader in delivering trusted, quality medications on oral film. Every medicine is different, so Aquestive follows a drug-by-drug approach for harnessing PharmFilm® technology to achieve target product profiles and clinical improvement goals.
Aquestive Therapeutics is the undisputed leader in developing and delivering medications via film, through our proprietary PharmFilm® technology. We’ve used our expertise to create a robust, proprietary CNS and complex molecule portfolio.
Learn about the medicines we’re reinventing to improve treatment options for patients.
PharmFilm® is a versatile, high-performance drug delivery technology that can be uniquely tailored to achieve a desired product profile with optimized absorption, bioavailability, and onset of action.
See how Aquestive is changing drug delivery to deliver meaningful clinical and therapeutic advances.
Our innovations in oral drug delivery aim to improve the treatment experience for patients with epilepsy and their caregivers who struggle with difficult or invasive modes of administration, complex treatment regimens, and inconsistent dosing and drug delivery.2 Our efforts to help patients and families extend beyond the clinic.
Aquestive is a specialty pharmaceutical company that advances and commercializes medicines to solve therapeutic problems and meaningfully improve people’s lives. We apply innovative drug delivery technology and scientific expertise to redesign important medicines. Our initial focus, supported by our current approved products and late-stage pipeline, is to improve medications and outcomes for patients with central nervous system (CNS) conditions.
Aquestive works hand-in-hand with our partners to address their toughest challenges—enhancing existing molecules and providing a development platform for new ones. We have comprehensive capabilities to advance medicines from pipeline to market. Partners can rely on our scientific and regulatory expertise, integrated development capabilities, and world-class clinical and commercial manufacturing operations. More than 2 billion commercial doses have been delivered with our PharmFilm® technology.
WARREN, N.J. , Feb. 20, 2020 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that it will report
FDA Acceptance of Libervant ™ (diazepam) Buccal Film NDA for Management of Seizure Clusters Potential for First Oral Diazepam-Based Therapy for Population of 1.2 million Refractory Epilepsy Patients Assigned Prescription Drug User Fee Act (PDUFA) Goal Date of September 27, 2020 WARREN, N.J. , Feb.
Pre-IND Meeting on AQST-108 Completed FDA Confirmed AQST-108 To Be Reviewed Under 505(b)(2) No Additional Clinical Studies Would Be Required Prior to Opening Proposed IND Pivotal Pharmacokinetic (PK) Clinical Trials Planned To Be Initiated Before Year End 2020 WARREN, N.J. , Feb.
1. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67–76.
2. Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in seizure emergencies: a systematic review. Epilepsy Behav. 2016;63:109–117.